SCHEMBL31401419

SCHEMBL31401419

O=C(O)c1cc(OC(F)F)cc(S(=O)(=O)C(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.41
FYN P06241 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.39
CYP1A2 P05177 1/20 0.37
ALOX15 P16050 1/20 0.35
GFER P55789 1/20 0.35
ADAM17 P78536 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
LMNA P02545 2/20 0.34
MAPT P10636 2/20 0.34
ATM Q13315 1/20 0.34
TSHR P16473 1/20 0.34
FBP1 P09467 2/20 0.33
DAGLA Q9Y4D2 2/20 0.33
ALDH1A1 P00352 1/20 0.33
MEN1 O00255 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
SENP8 Q96LD8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22926107 0.84 LCK (0.41) LCKFYNMRGPRX4CYP1A2ALOX15
SCHEMBL29639684 0.84 LCK (0.41) LCKFYNMRGPRX4CYP1A2ALOX15
SCHEMBL24017473 0.83 LCK (0.52) LCKFYNCYP1A2ALOX15SMN1; SMN2
SCHEMBL29728986 0.82 WDR5 (0.43) LCKFYNMRGPRX4CYP1A2TSHR
SCHEMBL23213468 0.82 WDR5 (0.43) LCKFYNMRGPRX4CYP1A2TSHR
SCHEMBL27893362 0.81 MRGPRX4 (0.47) LCKFYNMRGPRX4ALOX15GFER
SCHEMBL4235825 0.81 MRGPRX4 (0.47) MRGPRX4ALOX15GFERADAM17SMN1; SMN2
SCHEMBL23464784 0.80 AKR1C3 (0.39) LCKFYNMRGPRX4CYP1A2LMNA
SCHEMBL31401023 0.77 HCAR1 (0.48) LCKFYNCYP1A2LMNAALDH1A1
SCHEMBL24017267 0.76 LCK (0.44) LCKFYNCYP1A2SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed